Genetic association studies in epilepsy pharmacogenomics: lessons learnt and potential applications (Q36555922)

14 August 2017

1 reference

title

Genetic association studies in epilepsy pharmacogenomics: lessons learnt and potential applications (English)

1 reference

14 August 2017

1 reference

Chantal Depondt

1

1 reference

14 August 2017

Simon D Shorvon

series ordinal

2

1 reference

14 August 2017

language of work or name

1 reference

1 July 2006

1 reference

14 August 2017

1 reference

14 August 2017

volume

7

1 reference

14 August 2017

issue

5

1 reference

14 August 2017

page(s)

731-745

1 reference

Genetic predictors of the maximum doses patients receive during clinical use of the anti-epileptic drugs carbamazepine and phenytoin

14 August 2017

cites work

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.5.731

Patients with refractory seizures.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.5.731

Molecular mechanism of slow acetylation of drugs and carcinogens in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.5.731

Diverse point mutations in the human gene for polymorphic N-acetyltransferase

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.5.731

A single point mutation leading to loss of catalytic activity in human thiopurine S-methyltransferase

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.5.731

Autosomal dominant nocturnal frontal-lobe epilepsy: genetic heterogeneity and evidence for a second locus at 15q24

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.5.731

Early identification of refractory epilepsy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.5.731

The natural history of epilepsy in the era of new antiepileptic drugs and surgical treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.5.731

The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.5.731

Update on the mechanism of action of antiepileptic drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.5.731

Mechanisms of antiepileptic drug resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.5.731

Role of multidrug transporters in pharmacoresistance to antiepileptic drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.5.731

Tuberous sclerosis associated with MDR1 gene expression and drug-resistant epilepsy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.5.731

Over-expression of P-glycoprotein in malformations of cortical development.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.5.731

MDR1 gene expression in brain of patients with medically intractable epilepsy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.5.731

Overexpression of multiple drug resistance genes in endothelial cells from patients with refractory epilepsy.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.5.731

Multidrug-resistance protein 1 in focal cortical dysplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.5.731

Inhibition of multidrug transporters by verapamil or probenecid does not alter blood-brain barrier penetration of levetiracetam in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.5.731

Major vault protein, a marker of drug resistance, is upregulated in refractory epilepsy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.5.731

Overexpression of the human major vault protein in gangliogliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.5.731

RLIP76, a non-ABC transporter, and drug resistance in epilepsy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.5.731

Transient increase of P-glycoprotein expression in endothelium and parenchyma of limbic brain regions in the kainate model of temporal lobe epilepsy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.5.731

Lack of effects of prolonged treatment with phenobarbital or phenytoin on the expression of P-glycoprotein in various rat brain regions

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.5.731

P-glycoprotein: a major determinant of rifampicin-inducible expression of cytochrome P4503A in mice and humans

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.5.731

Multidrug resistance in epilepsy: rats with drug-resistant seizures exhibit enhanced brain expression of P-glycoprotein compared with rats with drug-responsive seizures.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.5.731

The role of cytochrome P450 enzymes in hepatic and extrahepatic human drug toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.5.731

The importance of drug interactions in epilepsy therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.5.731

Pharmacogenetics of the major polymorphic metabolizing enzymes.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.5.731

Specificity of human UDP-glucuronosyltransferases and xenobiotic glucuronidation

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.5.731

UDP-Glucuronosyltransferases

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.5.731

Anticonvulsant hypersensitivity syndrome: incidence, prevention and management

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.5.731

Mechanisms of idiosyncratic drug reactions: the case of felbamate.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.5.731

Screening for the potential of a drug candidate to cause idiosyncratic drug reactions

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.5.731

Lack of association between the C3435T polymorphism in the human multidrug resistance (MDR1) gene and response to antiepileptic drug treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.5.731

The effect of genetic polymorphism of cytochrome P450 CYP2C9 on phenytoin dose requirement

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.5.731

Genetic contribution to variable human CYP3A-mediated metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.5.731

Molecular basis of ethnic differences in drug disposition and response

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.5.731

Genetic predisposition to phenytoin-induced birth defects

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.5.731

Mutated nicotinic receptors responsible for autosomal dominant nocturnal frontal lobe epilepsy are more sensitive to carbamazepine

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.5.731

An epilepsy mutation in the beta1 subunit of the voltage-gated sodium channel results in reduced channel sensitivity to phenytoin

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.5.731

TNFalpha promoter region gene polymorphisms in carbamazepine-hypersensitive patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.5.731

Medical genetics: a marker for Stevens-Johnson syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.5.731

The role of catecholamines in seizure susceptibility: new results using genetically engineered mice

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.5.731

Norepinephrine is required for the anticonvulsant effect of the ketogenic diet

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.5.731

The -1021C->T DBH gene variant is not associated with epilepsy or antiepileptic drug response

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.5.731

The human genome project: past, present, and future

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.5.731

The International HapMap Project

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.5.731

Genome-wide association studies: theoretical and practical concerns

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.5.731

Genome-wide strategies for detecting multiple loci that influence complex diseases.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.5.731

Association study designs for complex diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.5.731

Pharmacogenetics in the laboratory and the clinic.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.5.731

Moving towards individualized medicine with pharmacogenomics

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.5.731

Pharmacogenetics goes genomic

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.5.731

Inhibitors of multidrug resistance to antitumor agents (MDR).

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.5.731

Use of verapamil as a potential P-glycoprotein inhibitor in a patient with refractory epilepsy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.5.731

Trastuzumab, a recombinant DNA-derived humanized monoclonal antibody, a novel agent for the treatment of metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.5.731

Gene expression profile analyses of cortical dysplasia by cDNA arrays

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.5.731

Transcriptional profiling in human epilepsy: expression array and single cell real-time qRT-PCR analysis reveal distinct cellular gene regulation

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.5.731

Pharmacogenetics and the practice of medicine

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.5.731

Pharmacogenetics and drug development: the path to safer and more effective drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.5.731

The mechanisms of action of commonly used antiepileptic drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.5.731

Characterization of the microsomal epoxide hydrolase gene in patients with anticonvulsant adverse drug reactions

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.5.731

Genetic analysis of microsomal epoxide hydrolase in patients with carbamazepine hypersensitivity

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.5.731

Association of Multidrug Resistance in Epilepsy with a Polymorphism in the Drug-Transporter GeneABCB1

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.5.731

21 January 2018

Identifiers

DOI

10.2217/14622416.7.5.731

1 reference

14 August 2017

1 reference